ストックスクリーナーアプリを入手
76.53
0.57%
0.43
アフターアワーズ：
76.53
Ani Pharmaceuticals Inc (ANIP) 最新ニュース
Christopher Mutz Sells 417 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock - MarketBeat
Ori Gutwerg Sells 2,060 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock - MarketBeat
Ani pharmaceuticals head of rare disease sells $30k in stock - Investing.com
ANIP SEC FilingsAni Pharmaceutic 10-K, 10-Q, 8-K Forms - Stock Titan
ESPR to Boost Cardiovascular Portfolio With Corstasis Buyout for $75M - Finviz
Director at ANI Pharmaceuticals (ANIP) sells 6,000 shares - Stock Titan
SVP & CFO At ANI Pharmaceuticals Buys $1.72M of Stock - Benzinga
833K Reasons To Be Bullish On ANI Pharmaceuticals Stock - Benzinga
SVP Of ANI Pharmaceuticals Makes $1.00M Buy - Benzinga
SVP Of ANI Pharmaceuticals Purchased $464K In Stock - Benzinga
ANI Pharmaceuticals (ANIP) Stock Analysis: A Compelling 47% Upside Potential Awaits Investors - DirectorsTalk Interviews
ANI Pharmaceuticals Targets $1B+ Sales in 2026, Pivots to Rare Disease Growth at Raymond James Conf. - MarketBeat
ANI Pharmaceuticals at Raymond James Conference: Rare Disease Focus By Investing.com - Investing.com Canada
ANI Pharmaceuticals Highlights Updated Non-GAAP Metrics to Investors - TipRanks
ANI Pharmaceuticals projects >$1B revenue in 2026, guides $275–$290M adjusted EBITDA - TradingView
ANI Pharmaceuticals (NASDAQ:ANIP) Releases FY 2026 Earnings Guidance - MarketBeat
ANI Pharmaceuticals : Corporate Presentation March 2026 - marketscreener.com
ANI Pharmaceuticals (NASDAQ: ANIP) guides to over $1B in 2026 revenue - Stock Titan
ANI Pharmaceuticals (NASDAQ: ANIP) exec granted 11,116 shares - Stock Titan
ANI Pharmaceuticals (ANIP) SVP receives stock award, withholds shares for taxes - Stock Titan
ANI Pharmaceuticals (ANIP) exec logs stock award and tax share disposal - Stock Titan
ANI Pharmaceuticals (ANIP) CEO logs restricted stock grant and tax-withholding share disposition - Stock Titan
ANI Pharmaceuticals (ANIP) SVP logs stock grant and tax withholding in Form 4 - Stock Titan
ANI Pharmaceuticals (ANIP) SVP reports stock award, tax withholding and LLC-held shares - Stock Titan
ANI Pharmaceuticals (ANIP) HR chief reports stock award and tax withholding - Stock Titan
Restricted stock grant for ANI Pharmaceuticals (ANIP) general counsel - Stock Titan
ANI Pharmaceuticals (ANIP) CFO awarded restricted stock and has shares withheld for taxes - Stock Titan
LLY Wins CHMP Nod for Olumiant's Expanded Use in Alopecia Areata - Finviz
ANI Pharmaceuticals Q4 2025: Strong Growth, But Execution Risks Emerge (NASDAQ:ANIP) - Seeking Alpha
William Blair Investment Management LLC Sells 141,856 Shares of ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Quantbot Technologies LP Has $4.20 Million Position in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Does Record 2025 Profitability and Reaffirmed 2026 Outlook Change The Bull Case For ANI Pharmaceuticals (ANIP)? - simplywall.st
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q4 2025 Earnings Call Transcript - Insider Monkey
ANI Pharmaceuticals (NASDAQ:ANIP) Beats Expectations in Strong Q4 CY2025, Stock Jumps 12.4% - The Globe and Mail
Clover Health, Alignment Healthcare, Solventum, ANI Pharmaceuticals, and Guardant Health Shares Plummet, What You Need To Know - The Globe and Mail
Decoding ANI Pharmaceuticals Inc (ANIP): A Strategic SWOT Insigh - GuruFocus
ANI Pharma Q4 2025 slides: rare disease shift drives 44% revenue growth - Investing.com Australia
ALIM Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Earnings call transcript: ANI Pharmaceuticals Q4 2025 earnings beat expectations - Investing.com Nigeria
ANI Pharmaceuticals Inc (ANIP) Q4 2025 Earnings Call Highlights: Record Revenue and Strong ... By GuruFocus - Investing.com Canada
ANI Pharmaceuticals Reports Strong Q4 Earnings Growth - Intellectia AI
ANI Pharmaceuticals Reports Q4 Net Income Growth - Intellectia AI
RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus - Finviz
ANI Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:ANIP) 2026-02-27 - Seeking Alpha
TGTX Q4 Earnings Lag Estimates, Briumvi Sales Drive Top Line - Finviz
ANI Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
ANI Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
ANI Pharma (ANIP) Q4 2025 Earnings Call Transcript - The Globe and Mail
ANI Pharmaceuticals Q4 Earnings Call Highlights - Yahoo Finance
ANI Pharmaceuticals Turns Profit, Rare Disease Sales Surge 50% - Benzinga
ANI Pharmaceuticals Posts Record 2025 Results on Rare Disease Growth - TipRanks
ANI Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
ANI Pharmaceuticals (ANIP) Stock: Revenue Jumps 44% as Rare Disease Pipeline Transforms Outlook - CoinCentral
Ani Pharmaceuticals, Inc. Reaffirms Revenue Guidance for the Full Year 2026 - marketscreener.com
ANI Pharmaceuticals (ANIP) Surpasses Q4 Earnings and Revenue Estimates - Yahoo Finance
ANI PHARMACEUTICALS ($ANIP) Releases Q4 2025 Earnings - Quiver Quantitative
ANI Pharmaceuticals Reaffirms FY26 Outlook; Swings To Profit In Q4; Stock Up 7.6%Update - Nasdaq
ANI Pharmaceuticals' Q4 Adjusted Earnings, Revenue Rise - marketscreener.com
ANI PHARMACEUTICALS INC SEC 10-K Report - TradingView
ANI Pharmaceuticals Reports Record Fourth Quarter and Full Year 2025 Financial Results - TradingView
ANI Pharmaceuticals Q4 Earnings Assessment - Benzinga
(ANIP) ANI Pharmaceuticals Expects 2026 Revenue Range $1.06B$1.12B, vs. FactSet Est of $1.01B - marketscreener.com
(ANIP) ANI Pharmaceuticals Expects 2026 Adjusted EPS Range $8.83$9.34, vs. FactSet Est of $8.76 - marketscreener.com
Earnings Flash (ANIP) ANI Pharmaceuticals, Inc. Reports Q4 Revenue $247.1M, vs. FactSet Est of $231.1M - marketscreener.com
Earnings Flash (ANIP) ANI Pharmaceuticals, Inc. Posts Q4 Adjusted EPS $2.33 per Share, vs. FactSet Est of $1.99 - marketscreener.com
Rare disease drug Cortrophin Gel drives 43.8% sales jump at ANI - Stock Titan
ANI Pharmaceuticals (ANIP) Profitability Turn In Q4 2025 Tests Premium P/E Narrative - Sahm
ANI Pharmaceuticals set to report earnings as Cortrophin drives shift By Investing.com - Investing.com UK
A Look Ahead: ANI Pharmaceuticals's Earnings Forecast - Benzinga
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
0.21%
1.77%
大文字化:
|
ボリューム (24 時間):